

## Varicose Vein Treatment Market : An Escalating Sector with Projected Growth to Reach USD 589.06 million by 2025

The global varicose vein treatment market is projected to reach \$ 589.06 million by 2025, growing at a CAGR of 5.7% from 2018 to 2025.

PORTLAND, OR, UNITED STATES, May 25, 2023 /EINPresswire.com/ -- The global Varicose vein treatment market was valued at \$ 376.64 million in 2017, and is projected to reach \$ 589.06 million by 2025, growing at a CAGR of 5.7% from 2018 to 2025.



The Varicose vein treatment market

refers to the global market for medical devices and procedures used to treat varicose veins, a condition where veins become swollen, twisted, and enlarged. Varicose veins can cause pain, discomfort, and skin ulcers, and can increase the risk of blood clots.

The market includes a variety of treatment options, including Endovenous laser treatment (EVLT), radiofrequency ablation (RFA), sclerotherapy, and surgical procedures. Some of the key players in the varicose vein treatment market include Medtronic, Lumenis, Alma Lasers Ltd., Angiodynamics, Inc., Biolitec AG, BTG PLC, Energist Ltd., Sciton Inc., WONTECH Co., Ltd., and Syneron.

The market is expected to see significant growth in the coming years, driven by factors such as the increasing prevalence of varicose veins, the rising demand for minimally invasive procedures, and the growing availability of advanced treatment

0000000 00000 0000 00 000000: <u>https://www.alliedmarketresearch.com/request-</u> sample/5184

000000, 00000000, 000 0000000000-

The growth of the global varicose vein treatment market is driven by the rise in incidences of varicose vein problem, increase in geriatric population, and technological advancements in varicose vein treatment devices. Additionally, growth of awareness in emerging economies would provide lucrative opportunities to emerging market players in the near future. However, dearth of skilled healthcare professionals and occasional product recall impede market growth.

Even though Covid-19 is a viral infection, the overlapping radiological and clinical features with bacterial respiratory tract infection demand oral antibiotics.

Several virologists claim that prescribing antibiotics for Covid-19 patients could create more resilient virus, which decreased the demand for antibiotics.

Injection sclerotherapy segment projected to occupy the largest share in the near future.

The injection sclerotherapy segment generated almost three-fifths of the global revenue in 2017 and is expected to continue its dominance through 2025, owing to the accurate nature of its result. However, the endovenous ablation segment is expected to grow at the highest CAGR of 6.9% during the forecast period, owing to its ability to eliminate the collapsed vein through the body's natural process.

Ablation devices segment is poised to encounter the highest growth from 2018 to 2025, a CAGR of 7.3%, as these devices are non-invasive and reduce recovery time. However, the sclerotherapy injection segment is projected to remain the dominant segment through the forecast period and occupy more than half of the global share.

000 0000000 000000 00: https://www.alliedmarketresearch.com/purchase-enquiry/5184

Regionally, Asia-Pacific would grow at the highest CAGR of 7.8% from 2018 to 2025, on account of rising consumer awareness, increase in geriatric population, and the growing adoption of advanced technology such as laser ablation and radiofrequency ablation.

Based on procedure, the sclerotherapy segment is expected to experience rapid growth in the market and is projected to grow at a CAGR of 5.5% from 2018 to 2025

Based on product, the ablation devices segment is expected to experience rapid growth in the market and is projected to grow at a CAGR of 7.3% from 2018 to 2025.

Based on end user, the hospital segment held approximately half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.

Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 7.8% during the forecast period.

Gene Synthesis Market: https://www.alliedmarketresearch.com/gene-synthesis-market-A39015

Mobile Tomography Market: <u>https://www.alliedmarketresearch.com/mobile-tomography-market-</u> <u>A31901</u>

Plasma Fractionation Market: <u>https://www.alliedmarketresearch.com/plasma-fractionation-</u> <u>market</u>

Influenza Vaccine Market: https://www.alliedmarketresearch.com/influenza-vaccines-market

## 0000000:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

## 0000000:

David Correa 5933 NE Win Sivers Drive 205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com

David Correa Allied Analytics LLP +1 800-792-5285 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/635767014

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.